Claims for Patent: 10,322,162

Summary for Patent: 10,322,162

Title:	Methods and pharmaceutical compositions for the treatment of ischemic conditions
Abstract:	The present invention relates to methods and pharmaceutical compositions for the treatment of ischemic conditions. In particular, the present invention relates to a method of treating an ischemic condition in a subject in need thereof comprising administering the subject with a polypeptide comprising an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino acid residue at position 186 to the amino acid residue at position 406 in SEQ ID NO: 1.
Inventor(s):	Germain; Stephane (Paris, FR), Berdeaux; Alain (Creteil, FR), Tissier; Renaud (Creteil, FR), Ghaleh-Marzban; Bijan (Creteil, FR), Monnot; Catherine (Paris, FR), Galaup; Ariane (Paris, FR)
Assignee:	INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) COLLEGE DE FRANCE (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Creteil, FR) UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE (Creteil, FR) ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) (Paris, FR) ECOLE NATIONALE VETERINAIRE D\'ALFORT (ENVA) (Maisons-Alfort, FR)
Application Number:	15/541,422
Patent Claims:	1. A method of treating an ischemic organ or tissue in a subject in need thereof comprising administering to the subject a synthetic ANGPTL4 polypeptide fragment comprising an amino acid sequence as set forth from position 186 to position 406 in SEQ ID NO:1, provided that said polypeptide is not SEQ ID NO:1, wherein the synthetic ANGPTL4 polypeptide fragment is administered in an amount sufficient to preserve vascular endothelial cell barrier integrity in the ischemic organ or tissue. 2. The method of claim 1 wherein the ischemic organ or tissue is the result of renal ischemia, retinal ischemia, brain ischemia or myocardial ischemia. 3. The method of claim 1 wherein the subject is suffering from at least one condition is-selected from the group consisting of coronary artery bypass graft surgery, global cerebral ischemia due to cardiac arrest, focal cerebral infarction, cerebral hemorrhage, hemorrhage infarction, hypertensive hemorrhage, hemorrhage due to rupture of intracranial vascular abnormalities, subarachnoid hemorrhage due to rupture of intracranial arterial aneurysms, hypertensive encephalopathy, carotid stenosis or occlusion leading to cerebral ischemia, cardiogenic thromboembolism, stroke, spinal stroke and spinal cord injury, vasculitis, macular degeneration, myocardial infarction, cardiac ischemia and supraventricular tachyarrhythmia. 4. The method of claim 1 wherein the synthetic ANGPTL4 polypeptide fragment is administered sequentially or concomitantly with a standard method selected from the group consisting of reperfusion of the ischemic organ by angioplasty, percutaneous coronary intervention, thrombolysis and coronary surgery. 5. The method of claim 1 wherein the synthetic ANGPTL4 polypeptide fragment is administered sequentially or concomitantly with a thrombolyic agent selected from the group consisting of reteplase, alteplase, urokinase, prourokinase, anisoylated purified streptokinase activator complex, and streptokinase. 6. The method of claim 1 wherein the synthetic ANGPTL4 polypeptide fragment is fused to a Fc domain of an immunoglobulin. 7. A method of treating acute myocardial infarction in a patient in need thereof comprising the steps of i) restoring blood supply in cardiac ischemic tissue, and ii) preserving vascular endothelial cell bather integrity of said cardiac ischemic tissue by administering to said patient a therapeutically effective amount of a synthetic ANGPTL4 polypeptide fragment to reduce infarct size, hemorrhage, and no-reflow, where steps i) and ii) are performed sequentially or concomitantly and wherein the synthetic ANGPTL4 polypeptide fragment comprises an amino acid sequence as set forth from position 186 to position 406 in SEQ ID NO:1, provided that said polypeptide is not SEQ ID NO:1. 8. A method of treating at least one ischemic organ or tissue in a patient in need thereof, comprising the steps of restoring blood supply in the at least one ischemic organ or tissue selected from the group consisting of heart, kidney, retina and brain; and administering to said patient a therapeutically effective amount of a synthetic ANGPTL4 polypeptide fragment having an amino acid sequence as set forth in SEQ ID NO:1 from position 186 to position 406, provided that said polypeptide is not SEQ ID NO:1; wherein said restoring and administering steps are performed sequentially or concomitantly, and wherein vascular endothelial cell barrier integrity of the at least one ischemic organ or tissue is preserved.

Details for Patent 10,322,162

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2035-01-06
Genentech, Inc.	ACTIVASE	alteplase	For Injection	103172	11/13/1987		2035-01-06
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172	09/04/2001		2035-01-06
Chiesi Usa, Inc.	RETAVASE	reteplase	For Injection	103786	10/30/1996		2035-01-06